Skip to main content
. 2021 Dec 27;13(12):2113–2127. doi: 10.4254/wjh.v13.i12.2113

Table 4.

Biochemical response to oral vancomycin and Sclerosing Cholangitis Outcomes in Pediatrics index score of 12 patients with autoimmune liver disease treated with oral vancomycin

Patients/diagnosis
Age at OVT (yr)
AST (NV ≤ 45 U/L)
ALT (NV ≤ 45 U/L)
GGT (NV ≤ 50 U/L)
Response to OVT 1 SCOPE index score2
Time on OVT (mo)
OVT side-effect
Overall FU3 (mo)
Before OVT
After OVT
TTN
Result
Before OVT
After OVT
TTN
Result
Before OVT
After OVT
TTN
Result
Before OVT
After OVT
AIH 5.4 212 39 4 mo NV 147 17 6 mo NV 73 22 6 mo NV Complete 3 low risk 0 low risk 99 None 113
AIH 11.8 251 31 2 mo NV 359 39 9 mo NV 26 34 8 mo NV Complete 3 low risk 0 low risk 72 None 73
ASC 16.8 98 47 3 mo < 1.5 NV 140 70 4 < 1.5 NV 39 83 4 < 1.5 NV Partial 8 high risk 8 high risk 16 None 26
ASC 4.8 86 28 7 d NV 156 38 14 d NV 84 44 14 d NV Complete 4 medium risk 1 low risk 37 None 39
ASC 13.1 60 14 1 mo NV 365 38 3 mo NV 68 27 4 mo NV Complete 5 medium risk 2 low risk 31 None 84
ASC 15.2 71 40 14 mo NV 140 56 14 mo < 1.5 NV 52 164 12 mo - None 6 high risk 6 high risk 6 None 68
ASC 17.4 113 65 1 mo < 1.5 NV 205 141 1 mo - 49 226 1 mo - None 6 high risk 4 medium risk 3 None 52
ASC 15 407 30 6 mo NV 856 35 6 mo NV 61 28 1 mo NV Complete 5 medium risk 2 low risk 40 None 49
ASC 17.3 102 37 2 mo NV 111 36 2 mo NV 135 82 5 mo < 1.5 NV Partial 6 high risk 4 medium risk 18 None 61
ASC 12.5 76 31 2 mo NV 124 40 7 mo NV 86; TX 42 6 mo NV Complete 5 medium risk 4 medium risk 47 None 135
ASC 13.9 123 155 - - 165 154 - - 165 1800 - - None 8 high risk 8 high risk 6 None 86; TX
ASC 13.2 141 135 - - 156 180 - - 71 mo (range 26-165) 136 - - None 7 high risk 7 high risk 4 None 165
Response to OVT 10/12 (83%) 9/12 (75%) 8/12 (67%) Median: 34 (range 1-99) 71 (range 26-165)
1

Complete response is defined as “normalization of all three liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT)]”, partial response as “AST, ALT or GGT levels decreasing to < 1.5 × ULN without reaching normal value”, and no response as “no significant changes in liver enzymes”.

2

Sclerosing Cholangitis Outcomes in Pediatrics: Points 0-3: Low risk; Points 4-5: Medium risk; Points 6-11: High risk.

3

Time from diagnosis to last follow up visit.

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; OVT: Oral vancomycin treatment; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; TTN: Time to normalize or to achieve the lowest value; NV: Normal value; FU: Follow up; SCOPE: Sclerosing Cholangitis Outcomes in Pediatrics.